EP 1409534 A2 20040421 - PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING HUMAN TUMORS, WHICH EXPRESS THE TUMOR ANTIGEN MUCIN AND/OR THE CARCINOEMBRYONIC ANTIGEN (CEA), AND THE USE THEREOF
Title (en)
PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING HUMAN TUMORS, WHICH EXPRESS THE TUMOR ANTIGEN MUCIN AND/OR THE CARCINOEMBRYONIC ANTIGEN (CEA), AND THE USE THEREOF
Title (de)
PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG UND PROPHYLAXE VON HUMANEN TUMOREN, DIE DAS TUMORANTIGEN MUZIN UND/ODER DAS CARCINOEMBRYONALE ANTIGEN (CEA) EXPRIMIEREN UND IHRE VERWENDUNG
Title (fr)
COMPOSITION PHARMACEUTIQUE POUR ASSURER LE TRAITEMENT ET LA PROPHYLAXIE DE TUMEURS CHEZ L'HOMME, QUI EXPRIMENT L'ANTIGENE TUMORAL MUCINE ET/OU L'ANTIGENE CARCINO-EMBRYONNAIRE ET SON UTILISATION
Publication
Application
Priority
- DE 0003443 W 20000926
- DE 19948105 A 19990927
Abstract (en)
[origin: WO0124832A2] The invention relates to a pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (CEA), and to the use thereof as a vaccine in humans for activating the immune system. According to the invention, a pharmaceutical composition is provided comprising a plasmid ( naked DNA ) which contains, as a therapeutic gene, the human mucin gene MUC1, active fragments thereof or at least 3 repeats of amino acid sequence SEQ No. 1, and/or comprising another plasmid ( naked DNA ) which contains, as a therapeutic gene, the gene for the human carcinoembryonic antigen (CEA) SEQ No. 2.
[origin: WO0124832A2] According to the invention, a pharmaceutical composition is provided comprising a plasmid ( naked DNA ) which contains, as a therapeutic gene, the human mucin gene MUC1, active fragments thereof or at least 3 repeats of amino acid sequence SEQ No. 1, and/or comprising another plasmid ( naked DNA ) which contains, as a therapeutic gene, the gene for the human carcinoembryonic antigen (CEA) SEQ No. 2. The pharmaceutical composition is preferably provided as a vaccine and the plasmids having the respective therapeutic gene are applied either individually or together according to the respective tumor.
IPC 1-7
IPC 8 full level
C07K 14/47 (2006.01); C07K 14/705 (2006.01); A61K 38/00 (2006.01); A61K 48/00 (2006.01)
CPC (source: EP)
C07K 14/4727 (2013.01); C07K 14/70503 (2013.01); A61K 38/00 (2013.01); A61K 48/00 (2013.01)
Citation (search report)
See references of WO 0124832A2
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0124832 A2 20010412; WO 0124832 A3 20020418; AU 1991901 A 20010510; DE 10048710 A1 20011004; EP 1409534 A2 20040421
DOCDB simple family (application)
DE 0003443 W 20000926; AU 1991901 A 20000926; DE 10048710 A 20000926; EP 00982945 A 20000926